|
PUBLICATIONS
1. Jensen RL, Origitano
TC, Lee, YS, Weber M, and Wurster RD: In-Vitro Growth Inhibition of Growth
Factor-Stimulated Meningioma Cells by Calcium Channel Antagonists. Neurosurgery
36:365-374,1995.
2. Jensen RL, Lee YS, Guijarti M, Origitano TC, Wurster
R, and Reichman OH: Inhibition of In-vitro Meningioma Proliferation After
Growth Factor Stimulation by Calcium Channel Antagonists Part II: Additional
Growth Factors, Growth Factor Receptor Immunohistochemistry, and Intra-
cellular Calcium Measurements. Neurosurgery 37:937-947,1995.
3. Jensen RL,Stone JL and Hayne R: Use of the Horsley-Clarke
Stereotactic Head Frame in Humans. Proceedings of the Meeting of the American
Society for Stereotactic and Functional Neurosurgery, Marina del Rey,
Calif.,1995,Part I Stereotact Funct Neurosurg 65: 194-197, 1995.
4. Jensen RL, Stone JL and Hayne R: Introduction of the
Human Horsley- Clarke Stereotactic Head Frame. Neurosurgery 38: 563-567,1996.
5. Jensen RL, Hahn YS, Ciro E: Risk Factors of Intracranial
Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review.
Surgical Neurology 47 :16-22, 1997.
6. Jensen RL, and Stone JL: Benjamin Winslow Dudley and
Early American Trephination For Posttraumatic Epilepsy. Neurosurgery 43:263-268,
1997.
7. Jensen RL, Leppla D, Rokosz N, and Wurster RD: Matrigel
augments xenograft transplantation of meningioma cells into athymic mice.
Neurosurgery 42: 130-136, 1998.
8. Jensen RL: Growth Factor Mediated Angiogenesis in
the Malignant Progression of Glial Tumors. A Review. Surgical Neurology
49: 189-96, 1998.
9. Kristopulos T, Jensen RL, Lee J, and Guijarti M: Clostridium
perfringens: as a rare cause of postoperative spinal surgery meningitis.
Surgical Neurology 51: 448-51, 1999.
10. Jellish WS, Jensen RL, Anderson DE and Shea JF: Intraoperative
electromyographic assessment of recurrent laryngeal nerve stress and pharyngeal
injury during anterior cervical spine surgery with Caspar instrumentation.
J Neurosurgery (Spine 2) 91 : 170-174, 1999.
11. Jensen RL., M Petr, and Wurster RD. Calcium channel
antagonist effect on in vitro meningioma signal transduction pathways
after growth factor stimulation. Neurosurgery 46 : 692-703, 2000.
12. Galloway EB, Jensen RL, Dailey AT, Thompson BG, and
Shelton C. Role of Topical Steroids in Reducing Dysfunction After Nerve
Injury. Laryngoscope 110: 1907-1910, 2000.
13. Jensen RL, and Wurster RD. Calcium channel antagonists inhibit growth
of subcutaneous xenograft meningiomas in nude mice. Surgical Neurology.
55: 275-283, 2001.
14. Shrieve DC, Watson GA, Jensen RL, and Leavitt DL:
Conformity of LINAC-based stereotactic radiosurgery using dynamic conformal
arcs and mini-multileaf collimator. Int J Radiation Oncology Biol Phys.51:
126 Suppl 1, 2001.
15. Jensen RLL, Soleau S, Bhayani MK, and Christiansen
D: Expression of hypoxia inducible factor 1± and correlation with preoperative
embolization of meningiomas. J Neurosurgery 97: 658-667, 2002.
16. Rao G and Jensen RL: Coexistant cerebral metastasis
and cavernous. J Neurol Neurosurg Psychiatry 74: 105, 2003.
17. Ragel B and Jensen RL: New approaches for the treatment
of refractory meningiomas. Cancer Control 10: 148-158, 2003.
18. Kan Peter and Jensen RL: Primary malignant cerebropontine
angle melanoma presenting as a presumed meningioma: Case report and review
of the literature. Skull Base Surgery 13: 159-166, 2003.
19. Liu JK, Schmidt M, MacDonald JD, Jensen RL, and Couldwell
WT: Hypophyseal transposition (hypophysopexy) for radiosurgery of pituitary
turmos involving the cavernous sinus. Technical note. Neurosurg Focus
14: Article 11, 2003.
20. Liu JK, O'Neill B, Orlandi RR, Moscatello AL, Jensen RL,
and Couldwell WT: Endoscopic-assisted craniofacial resection of esthesioneuroblastoma:
Minimizing facial incisions. Technical note and report of 3 cases. Minimally
Invasive Neurosurgery 46: 310-315, 2003.
21. Gilbert E, Shelton C, Harnsberger R, Jensen RL: Meningioma
of the jugular foramen: Glomus jugulare mimic and surgical challenge.
Laryngoscope 114: 25-32, 2004 .
22. Kan P, Gottfried, O, Blumenthal D, Townsend J, and Jensen R. Oligodendroglioma
and Juvenile Pilocytic Astrocytoma Presenting as Synchronous Primary Brain
Tumors: Case Report and Review of the Literature. J Neurosurgery 100:
700-705, 2004.
23. Jensen RL, Gillespie D, House P, Layfield L, and
Shelton C: Endolymphatic Sac Tumors In Patients With And Without Von Hippel
Lindau Disease: The Role of VHL Genetic Mutation, VHL Protein and Hypoxia
Inducible Factor-1± (HIF-1±) Expression. J Neurosurgery 100: 488-497,
2004.
24. House P, Salzman K, Osborn A, MacDonald J, JJensen RL,
and Couldwell. W: Surgical Considerations Regarding Giant Dilations of
the Perivascular Spaces. J Neurosurgery 100:820-824, 2004.
25. Ragel B and Jensen RL: Pathophysiology of Meningiomas.
Seminars in Neurosurgery 14: 169-185, 2004.
26. Jensen RL: Cauda equina syndrome as a post-operative
complication of non-instrumentated lumbar spine surgery. Neurosurgical
Focus, June 15, 2004.
27. Shrieve DC, Hazard L, Boucher K, and Jensen RL: Dose
fractionation in stereotactic radiotherapy for parasellar meningiomas:
Radiobiological j considerations of efficacy and optic nerve tolerance.
J Neurosurg (Suppl l 3) 101: 390-395, 2004.
28. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher
T, Wessels BW: Safety and Feasibility of Convection-Enhanced Delivery
(CED) of Cotara for the treatment of malignant glioma: Initial experience
in 51 patients. Neurosurgery 56:1243-1253, 2005
29. Rogers L, Jensen RL, and Perry A: Chasing your dural
tail. Editorial accepted for publication in the Int J Rad Oncol Biol Phys,
2005.
30. Ragel B, Jensen RL, Gillespie D, Prescott S, and
Couldwell W: d Cyclooxygenase-2 (COX-2) Is Ubiquitously Expressed in Meningiomas
s and Treatment in Vitro and COX-2 Inhibitor Celecoxib Decrease Cell d
Growth: Potential Therapeutic Application. Accepted for Publication in
J Neurosurgery, September 2005.
31. Rao G, Klimo P, Jensen RL, MacDonald JD, and Couldwell
WT: Recurrent craniofacial meningiomas. Accepted to J Neurosurgery
32. Layfield LJ, Wilmore C, Tripp S, Jones C, and Jensen RL:
Epidermal growth factor receptor (EGFR) gene amplification and protein
expression in glioblastoma multiforme: Prognostic significance and relationship
to other prognostic factors: Submitted to Am J Pathology
33. Jensen RL, Ragel B, Whang K, and Gillepsie D: Hypoxia
inducible factor 1± Is the Major Regulator of Vascular Endothelial Growth
Factor (VEGF) Secretion in Human Gliomas. Submitted to Neurosurgery.
34. Rao G, Klimo P, Thompson CJ, Samlowski W, Chang M, Watson G, Shrieve
D, and Jensen RL: Stereotactic radiosurgery as therapy
for melanomas, renal carcinoma, and sarcoma brain metastases: Impact of
added surgical resection and whole brain radiotherapy. Submitted to Int
J Rad Onc Phys Biol.
35. Chern SS, Leavitt DD, Jensen RL, and Shrieve DC:
Is smaller better? Comparison of 3 mm and 5 mm leaf size for stereotactic
radiosurgery: A dosimetry study. Submitted to Int J Rad Oncol Physic Biol.
36. Kan P, Gottfried O, Liu JK, Blumenthal D, Townsend J, and Jensen
RL. Primary Yolk Sac Tumor of the Conus Medullaris: Case Report
and Review of the Literature. Submitted to J Neurooncology.
37. Jensen RL, Camano E, Couldwell WT: Mesial temporal
lobe lesion with new onset of gadolinium enhancement after 15 years of
observation but at surgery found to be a ganglioglioma. Submitted to J
Neuro Oncology
38. McCall T, Binning M, Blumenthal D, Jensen RL: Variation
of choroids plexus papilloma dissemination. Submitted to Neurosurgery.
39. Finn MA, Blumenthal DT, Salzman KL, Jensen RL: Transient
post-ictal MRI changes in patients with brain tumors may mimic disease
progression. Submitted to J Neurosurgery.
40. McCall T, Rao G, and Jensen RL: Development and rapid
growth of a desmoid tumor in the surgical corridor following suboccipital
craniotomy for recurrent low grade astrocytoma. Submitted to J Neurosurgery.
41. Rogers LR, Sills AK, Vogelbaum MA, Suh JH, Rock JP, Ellis TI, Stieber
VW, Asher AL, Fraser RW, Billingsley JS, Arrambide S, Jensen RL,
and Shaw E: Initial results of phase II study utilizing the Gliasite RTS
for the treatment of a resected single brain metastasis. Submitted to
Neurosurgery.
42. Ragel BT, Blumenthal DT, Browd SR, and Jensen RL:
Intracerebral Amyloidoma Can Mimic High Grade Glioma on Magnetic Resonance
Imaging and Spectroscopy (MRI/MRS). Submitted to Neurooncology.
43. Ragel BT, Couldwell WR, McCutcheon I, Wendlend M, Whang K, Gillespie
DL, and Jensen RL. A comparison of cell lines involved
in meningioma research. In preparation.
44. Jensen RL, Gillespie D, Ragel B, and Wurster RD:
Treatment of Human Meningiomas with Calcium Channel Antagonists Potentiates
Chemotherapeutic Response. In preparation.
45. Gupta DK, Baker DL, Robinson JC, Jensen RL, and Egain
TD: Cerebral venous sinus thrombosis as a cause of delayed awakening and
severe cerebral edema during an awake craniotomy for speech mapping. Submitted
to Neuroanesthesia
46. Ragel B, Whang K, Osborn AG, Townsend JJ, Jensen RL,
House P, and Couldwell: Clinical and radiographic analysis of eight subependymomas.
case series and review of the literature. Submitted J Neurosurgery.
47. Gillepsie D and Jensen RL: Short inhibitory RNA inhibition
of hypoxia a inducible factor-1 decreases glioma growth in vivo and invitro.
In a preparation.
48. Jensen RL, O'Rouke D, Sampson J, Warnick R, Sawaya
R: Resident a training in Neuro Onocology. Survey results of North American
Training Programs. In Preparation, will submit to J of Neuro Oncology.
PRESENTATIONS
1. Jensen RL, Davis RK, Straight RC. The Eradication
of Invasive Tumors with Intraoperative Photodynamic Therapy. Presented
at the Western Section of the Federation of Research, Carmel, California,
February, 1989.
2. Jensen RL, Davis RK, Straight RC. Intraoperative Photodynamic Therapy
for the Eradication of Aggressive and Invasive Tumors. Presented at The
American Academy of Otolaryngology-Head and Neck Surgery Research Forum
in New Orleans on September 25, 1989.
3. Jensen RL, Davis RK, and Straight RC. Photodynamic
Therapy with Photofrin II and Acridine Orange Combined. Presented at the
American Society for Lasers in Medicine and Surgery National Meeting in
Nashville, Tennessee. April 6,7 and 8, 1990.
4. Jensen RL, Davis RK, Straight RC. Combination Phototherapy
With Photofrin II and Acridine Orange. Presented at The American Academy
of Otolaryngology-Head and Neck Surgery Research Forum in San Diego, California
on September 9-13, 1990.
5. Jensen RL, Davis RK, Straight RC. A Comparison of
the Localization and Retention Profiles of Methylene Blue, Acridine Orange,
and Photofrin II. Presented at the American Society for Lasers in Medicine
and Surgery National Meeting in San Diego, California. April 29,30 and
May 1, 1991.
6. Jensen RL, Davis RK, Straight RC. A New Approach to
Photodynamic Therapy with Methylene Blue. Presented at the American Society
for Lasers in Medicine and Surgery National Meeting in San Diego, California.
April 29,30 and May 1, 1991.
7. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro
Growth Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists.
Presented at the North American Skull Base Society Scientific Session,
Orlando, Florida, February, 1994.
8. Jensen RL, Origitano TC, Wurster R, Lee YS: The use
of calcium channel blocking agents for inhibition of meningioma cell growth
in vitro: Laboratory studies and clinical implications. Presented at Neurosurgery
in Jackson Hole, Jackson Hole, Wyoming, March, 1994.
9. Jensen RL, Hahn YS, Ciro E: Fiberoptic Intracranial
Pressure Monitoring: Experience with 98 Consecutive Patients. Presented
at the American Association of Neurological Surgeons Annual Meeting, San
Diego, April, 1994.
10. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman
OH., Growth Factor-Stimulated Proliferation of in-vitro Meningiomas can
be Inhibited by Calcium Channel Antagonists. Presented at the Second Annual
Growth Control in Central Nervous System Tumors Symposium, Boston, MA,
May 20-21,1994.
11. Hahn YS, Jensen RL, Ciro E: Risk Factors of Intracranial
Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review.
Presented at The International Society for Pediatric Neurosurgeons Annual
Meeting, Birmingham, UK, September, 1994.
12. Hahn YS, Jensen RL, Ciro E: Risk Factors of Intracranial
Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review.
Presented at The Congress of European Society for Pediatric Neurosurgery,
Lyon, France, September, 21-23, 1994.
13. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro
Growth Inhibition of Growth Factor-Stimulated Meningioma Cells by Calcium
Channel Antagonists. Presented at The Congress of Neurological Surgeons
Annual Meeting, Scientific Session, Chicago, Illinois, October, 1994.
14. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman
OH: The Proliferation of Growth Factor-Stimulated Primary Meningioma Cell
Cultures can be Inhibited by Calcium Channel Antagonists. Presented at
the The Congress of Neurological Surgeons Annual Meeting, Tumor satellite
symposium, Chicago, Illinois, October 6-7, 1994.
15. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman
OH: Growth Factor-Stimulated Proliferation of In-vitro Meningiomas can
be Inhibited by Calcium Channel Antagonists. Presented at Annual Meeting
of Society for Neuroscience, Miami Beach, Florida, November 13-18,1994.
16. Jensen RL, Origitano TC, Wurster R, Lee YS: Growth
Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists.
Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird,
Utah, February 3-8, 1995.
17. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro
Growth Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists.
Presented at the North American Skull Base Society Sixth Annual Meeting,
Scientific Session, Naples, Florida, February 18-25, 1995.
18. Jensen RL, Stone JL, and Hayne RA: Introduction of
the Human Horsley- Clarke Stereotactic Frame. Presented at the Quadrennial
Meeting of The American Society For Stereotactic and Functional Neurosurgery,
Marina del Rey, California, March 8-11,1995.
20. Jensen RL, Lee YS, Guijarti M, Origitano TC, Wurster
RD and Reichman OH: Inhibition of In-vitro Meningioma Proliferation After
Growth Factor Stimulation by Calcium Channel Antagonists Part II: Additional
growth factors, growth factor receptors immunohistochemistry, and intracellular
calcium measurements. Presented at the American Association of Neuro-
logical Surgeons Annual Meeting, Orlando, Florida, April, 22-27, 1995.
21. Jensen RL, Anderson DE, Thalji Z, and Jellish S:
Intraoperative recurrent laryngeal nerve monitoring during anterior cervical
discectomy. Presented at the American Association of Neurological Surgeons
Annual Meeting, Minneapolis, Minnesota, April, 22-27, 1996.
22. Wurster RD and Jensen RL: Calcium channel antagonists
as anticancer agents. Presented at the Meeting of Anticancer Targets and
Strategies for the Twenty-First Century. Castres, France, October 9-11,
1996
23. Jensen RL and Stone JL: Stereotactic cerebral localization:
Origin, evolution and future. Presented at the Annual Meeting of Society
for Neuroscience, Washington, D.C. November 12-17,1996.
24. Jensen RL, Origitano TC, Wurster R, Reichman O.H:
Calcium channel antagonist growth inhibition of meningioma cell growth:
eludication of mechanism and in vivo experiments. Presented at the Richard
Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-8, 1997.
25. Jensen RL, Gruener G, and Origitano TC: Post-ventriculoperitoneal
shunt infection Parkinsonism. Case report, video exam, literature review.
Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird,
Utah, February 1-8, 1997.
26. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel
augments tumor take and tumor mass in xenograft transplantation of cultured
meningioma cells into athymic mice. Presented at the North American Skull
Base Society Eighth Annual Meeting, Scientific Session, Little Rock, Arkansas,
March 22-25, 1997.
27. Jensen RL, T. C. Origitano, Wurster R: Status of
current basic research of meningioma development and proliferation. A
review. Presented at the North American Skull Base Society Eighth Annual
Meeting, Scientific Session, Little Rock, Arkansas, March 22-25, 1997.
28. Jensen RL, Kristopulos C, Guijartic M, and Anderson
DE: Clostridium perfringes as a rare cause of postoperative spinal surgery
meningitis. Presented at the American Association of Neurological Surgeons
Annual Meeting, Denver, Colorado, April, 12-17, 1997.
29. Jensen RL: Meningioma Growth Inhibition by calcium
channel antagonists. Neurology/Neurosurgery Grand Rounds. University of
Utah School of Medicine. July 23, 1997.
30. Jensen RL, Leppla D, Rokosz N, Wurster R: Subcutaneous
xenograft transplanatation of meningioma cells into athymic mice using
a Matrigel matrix. Presented at the Congress of Neurological Surgeons
Annual Meeting, Scientific Session, New Orleans, Louisiana, Sept. 27-Oct.
2, 1997.
31. Jensen RL, Anderson DE, Thalji Z, and Jellish S:
Recurrent laryngeal nerve monitoring during anterior cervical spinal procedures
using intraoperative posterior pharyngeal electromyography. Presented
at the Congress of Neurological Surgeons Annual Meeting, Scientific Session,
New Orleans, Louisiana, September 27-October 2, 1997.
32. Jellish WS, Thalji A, Jensen RL, Anderson DE: Intraoperative
compound electromyography of posterior pharynx as a method to detect recurrent
layrngeal nerve injury during anterior cervical spine procedures. Presented
at the 1997 Annual Meeting of the Society of Anesthesiologists, San Diego,
CA. October 18-22. 1997.
33. Jellish WS, Thalji A, Jensen RL, Anderson DE: Electromyography
used during anterior cervical spine procedures to detect recurrent layrngeal
nerve injury. Presented at the 25th Annual Meeting of the Society of Neurosurgical
Anesthesia and Critical Care. San Diego, CA. October 17. 1997.
34. Jensen RL, and Wurster RD: Investigations of mechanisms
of calcium channel antagonist growth inhibition of meningioma cell growth
in vivo. Presented at the 27th Annual Meeting of Society for Neuroscience,
New Orleans, October 25-30,1997.
35. Jensen RL, and Stone JL: Benjamin Winslow Dudley
and early American trephination for posttraumatic epilepsy. Presented
at the 27th Annual Meeting of Society for Neuroscience, New Orleans, October
25-30,1997.
36. Jensen RL and Jellish S: Intraoperative posterior
pharyngeal electromyography for the prevention of recurrent laryngeal
nerve injury during anterior cervical spine procedures. Presented at the
Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February
1-8, 1998.
37. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel
augments the subcutaneous xenograft transplantation of meningioma cells
into athymic mice. Presented at the American Association of Neurological
Surgeons Annual Meeting, Scientific Session, Philadelphia, Pennsylvania,
April 25- 30, 1998.
38. Jensen RL, Anderson DE, Thalji Z, and Jellish S:
Intraoperative recurrent laryngeal nerve monitoring during anterior cervical
spine procedures with posterior pharyngeal electromyography. Presented
at the American Association of Neurological Surgeons Annual Meeting, Scientific
Session, Philadelphia, Pennsylvania, April 25-30, 1998.
39. Jensen RL, Gruener G, and Origitano TC: Post-ventriculoperitoneal
shunt infection Parkinsonism. Presented at the American Association of
Neurological Surgeons Annual Meeting, Scientific Session, Philadelphia,
Pennsylvania, April 25-30, 1998.
40. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel
augments the subcutaneous xenograft transplantation of meningioma cells
into athymic mice. Presented at AANS/CNS Tumor Satellite Symposium, Philadelphia,
Pennsylvania, April 30 - May 1, 1998.
41. Jensen RL Growth factor medicated angiogenesis in
the malignant progression of glial tumors. A review. Presented at AANS/CNS
Tumor Satellite Symposium, Philadelphia, Pennsylvania, April 30 - May
1, 1998.
42. Jensen RL Meningioma turmorigenesis and proliferation.
A review. Presented at AANS/CNS Tumor Satellite Symposium, Philadelphia,
Pennsylvania, April 30 - May 1, 1998.
43. Jensen RL, Petr M, Wurster RD. Calcium channel antagonist
effection of in vitro meningioma intracellular calcium and inositol phosphate
metabolism.Presented at the Congress of Neurological Surgeons Post Satellite
Meeting-Semi-Ah-Moo Resort, Blaine, Washington. October 10, 1998.
44. Jensen RL: Vascular Endothelial Growth Factor: Common
denominator of intracranial tumor vascularity, peritumoral edema, and
thromboembolic complications. University of Utah Neurology/Neurosurgery
Grand Rounds, October 14, 1998.
45. Jensen RL, Petr M, and Wurster RD: Calcium Channel
Antagonist alterations of intracellular calcium and inositol phosphate
signaling in human cultured meningiomas. Presented at the 28th Annual
Meeting of Society for Neuroscience, Los Angeles, November 7-12,1998.
46. Jensen RL: Vascular Endothelial Growth Factor-mediated
glioma angiogenesis requires simultanteous, multiple growth factor stimulation.
Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird,
Utah, January 30 - February 5, 1999.
47. Jensen RL, Petr M, and Wurster RD: In vitro meningioma
cell intracellular calcium and inositol phosphate are disrupted by calcium
antagonists. Presented at the American Association of Neurological Surgeons
Annual Meeting, Scientific Session, New Orleans, Louisana, April 24-29,
1999.
48. Jensen RL: Calcium channel antagonist effect on in
vitro meningioma signal transduction pathways after growth factor stimulation.
North American Skull Base Society 1999 Annual Meeting. Chicago, Illinois,
May 28-31, 1999.
49. Jensen RL: Long-Term Results with Foramen Magnum
and Craniocervical Junction Tumors. Panel discussant, Speaker. North American
Skull Base Society 1999 Annual Meeting. Chicago, Illinois, May 28-31,
1999.
50. Jensen RL: Preoperative Functional Work-up and Intraoperative
Mapping of Intrinsic Brain Tumors, and the Biology of Meningiomas. Visiting
Professor, Loyola University of Chicago October 12 -13, 1999
51. Jensen RL : Biology of Meningiomas. Invited speaker,
Plenary Session. Joint Section on Tumors. Congress of Neurological Surgeons
Annual Meeting, Boston, Massachusetts, October 30 - November 3, 1999.
52. Jensen RL, Wurster RD: Calcium channel antagonist
effect on in vitro meningioma signal transduction pathways after growth
factor stimulation. Congress of Neurological Surgeons Annual Meeting,
Boston, Massachusetts, October 30 - November 3, 1999.
53. Jensen RLL. Brain Protection. Anesthesiology Grand
Rounds. University of Utah School of Medicine, January 20, 2000.
54. Jensen RL: Vascular endothelial growth factor secretion
is mediated by growth factor stimulation and hypoxia. Richard Lende Winter
Neurosurgical Conference, Snowbird, Utah, January 29 - February 3, 2000.
55. Jensen RL, and Wurster RD. Vascular endothelial growth
factor (VEGF) secretion in meningiomas is regulated by hypoxia and growth
factors. 11th Annual Meeting of the North American Skull Base Society.
Scottsdale, Arizona, March 17-20, 2000.
56. Galloway EB, Jensen RLL, Dailey AT, Thompson BG,
and Shelton C. Topical Steroids: Do they reduce dysfunction following
nerve injury? Presented at the Western Section of the Triologic Society
Meeting, San Francisco, March, 2000.
57. Jensen RL, and Wurster RD. Calcium Channel Antagonists
Inhibit the Growth of Subcutaneous Xenograft Meningiomas in Nude Mice.
American Association of Neurological Surgeons, San Francisco, April 9-13,
2000.
58. Jensen RL: Mechanisms of Hypoxia-induced and Growth
Factor Stimulated Vascular Endothelial Growth Factor Secretion in Intracranial
Tumors. Fourth Biennial AANS/CNS Section on Tumor Satellite Symposium,
San Francisco, California, April 13-14, 2000.
59. Jensen RL: Management of Cerebral Metastatic Disease
2000. University of Utah Neurology/Neurosurgery Grand Rounds, April 19,
2000.
60. Jensen RL: Hypoxia Induced Vascular Endothelial Growth
Factor Secretion in Intracranial Tumors. 2000 Rocky Mountain Neurosurgical
Society. Alyeska, Alaska, June 24-28, 2000.
61. Jensen RL and Wurster RD. Calcium channel antagonist
effect on xenograft meningiomas: Growth Studies, histological analysis,
and proliferative indices. Congress of Neurological Surgeons Annual Meeting,
San Antonio, Texas, September 23-28, 2000.
62. Jensen RL: Diseases of the Cavernous Sinus: Work-up,
Management, and Surgical Anatomy. University of Utah Neurology Neurosurgery
Grand Rounds. September 20, 2000.
63. Jensen RL: Vascular Endothelial Growth Factor Expression
is Controlled by Hypoxia and Growth Factor Stimulatio in Intracranial
Tumors. Fifth Annual Meeting Society of Neuro-Oncology, Chicago, Illinois,
November 9-12, 2000.
64. Jensen RL: Postoperative cauda equina syndrome after
lumbar spine procedures. Richard Lende Winter Neurosurgical Conference,
Snowbird, Utah, January - February 2-8, 2001.
65. Jensen RL: The role of hypoxia inducible factor in
vascular endothelial growth factor secretion after growth factor stimulation
and hypoxia. American Association of Neurological Surgeons, Toronto, Ontario,
Canada, April 21-24, 2001.
66. Patel SJ, Laske D, Jensen RL, Asher A, and Chew T:
Phase 2 results of an open label study of interstitial 131I-ch-TNT-1/B
for the treatment of newly diagnosed or recurrent malignant glioma. American
Society of Clinical Oncology, May 2001.
67. Shrieve DC, Watson GA, Jensen RL, Heilbrun MP, and
Leavitt DL: Conformality of LINAC-based SRS utilizing dynamic arcs with
MMLC. ASTRO, 2001.
68. Jensen RLL: Hypoxia inducible factor-1± mediated
VEGF expression after hypoxic and growth factor stimulation in glioblastoma
multiforme. International Brain Tumor Meeting. Asheville, North Carolina,
May 26-31, 2001.
69. Rao G and Jensen RL: Co-existing cavernous angioma
and metastatic brain tumor. Imaging studies, pathology and management.
Rocky Mountain Neurosurgery Society, Steamboat Springs, June 16-21, 2001.
70. House P and Jensen RL: Temporal lobe subependymoma.
Case description and imaging studies. Rocky Mountain Neurosurgery Society,
Steamboat Springs, June 16-21, 2001.
71. Jensen RL: Tissue diagnosis in neurooncology; necessity
or antiquated by modern imaging techniques. Rocky Mountain Neurosurgery
Society, Steamboat Springs, June 16-21, 2001.
72. Jensen RL and Frantz D. Hypoxia inducible factor
1± mediated vascular endothelial growth factor secretion in intracranial
tumors. Congress of Neurological Surgeons. San Diego, California. September
29-October 4, 2001.
73. Jensen RL: Hypoxia inducible factor 1± in intracranial
tumors. University of Utah Neurology/Neurosurgery Grand Rounds, August
18, 2001.
74. Jensen RL, and Frantz D: The role of hypoxia inducible
factor-1 in vascular endothelial growth factor expression in glioblastoma
multiforme under normoxic and hypoxic conditions. Sixth Annual Meeting
Society of Neuro-Oncology, Washington, DC, November 15-18, 2001.
75. Wessels P, Jensen RL, Patel S, Nelson AB, Bouchet
CD, Shan J, and Chew T: Image fusion and patient specific dosimetry for
tumor response and toxicity evaluation in patients with gliomas undergoing
radionucliotide therapy. Sixth Annual Meeting Society of Neuro- Oncology,
Washington, DC, November 15-18, 2001.
77. Kan Peter and Jensen RL: Indolent Jugular Foramen
Primary Central Nervous System Melanoma Though To Be A Meningioma. Richard
Lende Winter Neurosurgical Conference, Snowbird, Utah, February 3-8, 2002.
78. Jensen RL, Soleau S, Bhayani MK, and Christiansen
D: Hypoxia Inducible Factor-1± (HIF-1±) Regulation of Vascular Endothelial
Growth Factor (VEGF) Secretion in Meningiomas: Effect of In vivo Preoperative
Embolization and In vitro Hypoxia on Primary Meningioma Cell Cultures.
Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February
3-8, 2002.
79. Jensen RLL, Treatment of Human Meningiomas with Calcium
Channel Antagonists. American Association of Neurological Surgeons Annual
meeting, Chicago, Illinois, April 5-10, 2002.
80. Panner AS, Zainelli GM, Jensen RL, Origitano TC,
and Wurster RD: Possible correlation between T-type calcium channel expression
and degree of proliferation of intracranial tumor cells. American Association
of Neurological Surgeons Annual meeting, Chicago, Illinois, April 5-10,
2002.
81. Jensen RL Hypoxia Inducible Factor-1 Control of Intracranial
Tumor Growth and Angiogenesis Presented at AANS/CNS Tumor Satellite Symposium,
Chicago, Illinois, April 11 - 12, 2002.
82. Jensen RL: Primary Central Nervous System Lymphoma:
Uncommon But Confounding Factor In Neuro-oncology. Rocky Mountain Neurosurgery
Society Annual Meeting, Sante Fe, New Mexico, June 14th-18th, 2002.
83. House P and Jensen RL: Endolymphatic Sac Tumors as
part of the von Hippel-Lindau syndrome: Molecular biology and relation
to Hypoxia Inducible Factor-1 regulation. Rocky Mountain Neurosurgery
Society Annual Meeting, Sante Fe, New Mexico, June 14th-18th, 2002.
84. Jensen RL, and Gillepsie D: Modificaton of Hypoxia
Inducible Factor-1 expression in Glioblastoma Multiforme Alters Growth
and Angiogenesis Seventh Annual Meeting Society of Neuro-Oncology, San
Diego, CA, November 21-24, 2002.
85. Watson GA, Romney D, Samlowski WE, Jensen RL, and
Shrieve DC: LINAC based stereotactic radiosurgery for renal cell and melanoma
brain metastases: prognostic factors for overall survival and local control.
Seventh Annual Meeting Society of Neuro-Oncology, San Diego, CA, November
21-24, 2002.
86. Jensen RL, Shrieve D, Fults D, and Watson G: Gliasite
Radiation Therapy System for Treatment of Recurrent Malignant Gliomas
and Metastatic Brain Tumors. University of Utah Experience. Richard Lende
Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.
87. Jensen RL, and Gillespie D: Hypoxia Inducible Factor-1
Expression in Glioblastoma Multiforme Controls Vascular Endothelial Growth
Factor Secretion, Angiogenesis, and Tumor Growth. Richard Lende Winter
Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.
88. Klimo P, Blumenthal D, and Jensen RL: Richter's syndrome-A
rare form of primary CNS lymphoma. Richard Lende Winter Neurosurgical
Conference, Snowbird, Utah, February 1-7, 2003.
89. Rao G, Watson G, Shrieve D, and Jensen RL: Experience
at the University of Utah with LINAC based stereotactic radiosurgery for
patients with “radioresistant” cerebral metastases. Richard Lende Winter
Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.
90. Ragel B and Jensen RL: New approaches for the treatment
of refractory meningiomas. Richard Lende Winter Neurosurgical Conference,
Snowbird, Utah, February 1-7, 2003.
91. Jensen RL. Cortical Mapping. Breakfast Seminar. American
Association of Neurological Surgeons Annual meeting, San Diego, CA, April
26-May 1, 2003.
92. Jensen RL. Discussant. Mouse Model of NF2-related meningioma. Scientific
Session I. American Association of Neurological Surgeons Annual meeting,
San Diego, CA, April 26-May 1, 2003.
93. Jensen RL and Gillepsie D. Hypoxia inducible factor-1 controls growth
and angiogenesis in glioblastoma multiforme. American Association of Neurological
Surgeons Annual meeting, San Diego, CA, April 26-May 1, 2003.
94. Jensen RL, Shrieve D, Fults D, and Watson G: Gliasite
Radiation Therapy System for Treatment of Recurrent Malignant Gliomas
and Metastatic Brain Tumors. University of Utah Experience. Submitted
for presentation at Rocky Mountain Neurosurgery Society Annual meeting,
Big Sky, MT, June 26-May 1, 2003.
95. Jensen RL: Hypoxia Inducible Factor-1 in the growth
and angiogenesis of human brain tumors. University of Utah Neuroscience
Student Retreat. Midway, Utah, August 22, 2003.
96. Kan P, Gottfied O, and Jensen RL: Oligodendroglioma
and juvenile pilocytic astrocytoma presenting as synchronous primary brain
tumors. Congress of Neurological Surgeons. Denver, Colorado. September
29-October 4, 2003.
97. Jensen RL and Gillespie D: Vascular endothelial growth
factor is inhibited by small interfering ribonucleic acid sequences directed
toward the hypoxia inducible factor 1 gene. Congress of Neurological Surgeons.
Denver, Colorado. September 29-October 4, 2003.
98. Rao G, Watson G, Shrieve D, Samlowski W, and Jensen RL:
Institutional Experience with LINAC based stereotactic radiosurgery for
patients with “radioresistant” cerebral metastases. Congress of Neurological
Surgeons. Denver, Colorado. September 29-October 4, 2003.
99. Gottfied O, Liu JK, and Jensen RL: Primary Intramedullary
Yolk Sac Tumor. Congress of Neurological Surgeons. Denver, Colorado. September
29-October 4, 2003.
100. House P and Jensen RL: Endolymphatic Sac Tumors
as part of the von Hippel-Lindau syndrome: Molecular biology and relation
to Hypoxia Inducible Factor-1 regulation. Congress of Neurological Surgeons.
Denver, Colorado. September 29-October 4, 2003.
101. Jensen RL: State of the Art Management of Brain
Metastastes. Invited luncheon panelist. Congress of Neurological Surgeons.
Denver, Colorado. September 29-October 4, 2003.
102. Liu JK, O'Neill B, Orlandi RR, Moscatello AL, Jensen RL,
and Couldwell WT: Endoscopic-assisted craniofacial resection of esthesioneuroblastoma:
Minimizing facial incisions. Technical note and report of 3 cases. Denver,
Colorado. September 29-October 4, 2003.
103. Jensen RL: Multimodality Treatment of Malignant
Gliomas. Invited luncheon panelist. Congress of Neurological Surgeons.
Denver, Colorado. September 29-October 4, 2003.
104. Jensen RL, and Gillespie D: Small Interfering Ribonucleic
Acid Sequences Directed Toward the Hypoxia Inducible Factor 1 Gene Inhibits
Vascular Endothelial Growth Factor Secretion in Malignant Glioma Cell
lines. Society for Neuro-Oncology, Eight Annual Meeting, Keystone Colorado,
November 13-16, 2003.
105. Jensen RL: Stereotactic Radiosurgery. University
of Utah Mechanical Engineering Graduate Seminar, November 21, 2003.
106. Jensen RL and Gillespie D: The Use of Small Inhibitory
Ribosnucleic Acid (siRNA) to inhibit Hypoxia-Inducible Factor-1 (HIF-1)
Expression as A Treatment for Malignant Gliomas. Richard Lende Winter
Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.
107. Gillespie D, and Jensen RL: Running interference:
Using short RNAs for targeted gene silencing in mammals. Richard Lende
Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.
108. Finn M, Blumenthal D, and Jensen RL: Transient post-ictal
MRI changes in patients with brain tumors may mimic disease progression.
Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6,
2004.
109. Liu J, Ragel BT, Whang K, Gillespie DL, Prescott SM, Couldwell WT,
and Jensen RL: R-Flurbiprofen inhibits cell proliferation
and induces apoptosis in pituitary adenoma cells in vitro. Richard Lende
Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.
110. Ragel B, Liu JK, Whang K, Gillespie DL, Couldwell WT, and Jensen
RL: Cyclooxygenase-2 (COX-2) in meningiomas: A potential therapeutic
target. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February
1-6, 2004.
111. Jensen RL, Kushnir V, Ragel B, and Gillespie D:
Calcium Channel Antagonists Increase the Efficacy of Chemotherapeutic
Agents Commonly Used for Treatment of Refractory Meningiomas. North American
Skull Base Society. New Orleans, LA, February 14-17, 2004.
112. Ragel B, Couldwell W, and Jensen RL: Cycloxygenase
2 (COX-2) is Expressed in Human Meningiomas and Does Not Correlate with
HIF-1 alpha or VEGF Expression. North American Skull Base Society. New
Orleans, LA, February 14-17, 2004.
113. Jensen RL: Breakfast with the Professor. North American
Skull Base Society. New Orleans, LA, February 14-17, 2004.
114. Jensen RL, and Gillespie D: Small Interfering Ribonucleic
Acid Sequences Directed Toward the Hypoxia Inducible Factor 1 Gene Inhibits
Vascular Endothelial Growth Factor Secretion in Malignant Glioma Cell
lines. American Association of Neurological Surgeons Annual meeting, Orlando,
Florida, May 1-6, 2004.
115. Ragel B, Couldwell W, and Jensen RL: Cycloxygenase
2 (COX-2) is Expressed in Human Meningiomas and Does Not Correlate with
HIF-1 alpha or VEGF Expression. American Association of Neurological Surgeons
Annual meeting, Orlando, Florida, May 1-6, 2004.
116. Jensen RL: Pitfalls in cerebral cortical mapping.
Invited participant. Breakfast seminar. American Association of Neurological
Surgeons Annual meeting, Orlando, Florida, May 1-6, 2004.
117. Ragel B; Liu JK; Gillespie DL; Whang K; Jensen RL;
Couldwell WT: NSAIDs as a Possible Treatment for Meningiomas. Presented
at the 39th annual meeting of the Rocky Mountain Neurosurgery Society,
Squaw Valley, CA, June 12-16, 2004.
118. Browd SR; Tucker J; Jensen RL; Lee J: fMRI for Neurosurgical
Mapping: Integration and Correlation with Intraoperative Mapping Techniques.
Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery
Society, Squaw Valley, CA, June 12-16, 2004.
119. Jensen RL, Kushnir V, Ragel BT, and Gillespie D:
Growth inhibition of chemotherapy for meningiomas is potentiated by calcium
channel antagonists. Presented at the 39th annual meeting of the Rocky
Mountain Neurosurgery Society, Squaw Valley, CA, June 12-16, 2004.
120. Jensen RL and Gillespie D: Hypoxia inducible factor-1
inhibition by short interfering RNA techniques for the treatment of malignant
gliomas. Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery
Society, Squaw Valley, CA, June 12-16, 2004.
121. Jensen RL: Implant considerations unique to Gliasite.
Invited Panelist at 2004 Gliasite Physician Conference, Chicago, Illinois.
122. Jensen RL: Novel treatments for glioblastoma multiforme.
American Association of National Cancer Registries. October 1, 2004. Salt
Lake City, Utah.
123. Jensen RL; Kushnir V; Ragel B; Gillespie D: Growth
Inhibition Of Meningiomas By Combined Chemotherapeutic And Calcium Channel
Antagonists. In Vitro And In Vivo Studies. Presented at the Congress of
Neurological Surgeons, San Francisco. October 16th-21st, 2004.
124. Ragel B, Liu JK, Whang K, Gillespie DL and Jensen RL;
NSAIDS as a possible treatment for meningiomas. Presented at the Congress
of Neurological Surgeons, San Francisco. October 16-21st, 2004.
125. Gillespie DL and Jensen RL: Running interference:
Using short RNAs for targeted gene silencing in mammals. Presented at
the Congress of Neurological Surgeons, San Francisco. October 16-21st,
2004.
126. Liu JK, Ragel BT, Whang K, Gillespie DL, Jensen RL,
Prescott SM, and Couldwell WT: R-Flurbiprofen downregulates cycloxygenase-2
(COX-2) and induces apoptosis in pituitary adenoma cells in vitro. Presented
at the Congress of Neurological Surgeons, San Francisco. October 16-21st,
2004.
127. Jensen RL, Gillespie D: Hypoxia inducible factor
1a is upregulated and is the principle mediator of VEGF secretion in malignant
gliomas. Presented at the AANS/CNS Section on Tumors Sixth Biennial Satellite
Symposium, San Francisco, October 21-22, 2004.
128. Jensen RL. Combined chemotherapeutic and calcium
channel antagonists for growth inhibition of meningioms, in vitro and
invivo studies. Society for NeuroOncology Ninth Annual Meeting, Toronto,
Canada, November 18-21, 2004.
129. Hitchcock Y, Bentz B, Jensen RL, and Sharma P: Second
high-grade sarcoma of the mandible within prophylatic cranial irradiation
field in a long term survivor of childhood acute lymphocytic leukemia.
International Connective Tissue Oncology Society, 2004.
130. Hazard L, Jensen RL, Chern SS, Leavitt DD, and Shrieve
DC: Conformity and normal tissue sparing of intensity modulated stereotactic
radiotherapy compared to dynamic conformal arc stereotactic radiotherapy.
ASTRO 2004.
131. Jensen RL: New Clinical Trials for Malignant Gliomas.
Utah State Neurological Society Meeting, Salt Lake City, Utah, December
8, 2005.
132. Jensen RL, Ragel B, Whang K,and Gillespie D: Calcium
Channel Antagonists Increases the Efficacy of Chemotherapeutic Agents
for Growth Inhibition of Benign and Malignant Meningiomas. In Vitro And
In Vivo Studies. Richard Lende Winter Neurosurgical Meeting. Snowbird
Utah, January 29- February 2, 2005.
133. Jensen RL, Gillespie D: Hypoxia inducible factor
1a is the major regulator of vascular endothelial growth factor secretion
in human gliomas. Accepted for presentation at the AANS Annual Meeting,
New Orleans, April 16- 21, 2005.
134. Jensen RL. The Spectrum of Adjuvant Therapy for
Brain Tumors. Breakfast Seminar. Accepted for presention at the AANS Annual
Meeting, New Orleans, April 16- 21, 2005.
135. Ragel B, and Jensen RL: Hypoxia-induced genes in
a malignant glioma cell in (U-251) by cDNA microarray analysis. Accepted
for presention at the AANS Annual Meeting, New Orleans, April 16- 21,
2005.
136. Ragel B, and Jensen RL: Celecoxib decreases the
growth of malignant meningioma cell line (IOMM-Lee) in the mouse xenograft
flank model. Accepted for presention at the AANS Annual Meeting, New Orleans,
April 16- 21, 2005.
137. Jensen RL and Gillepie DL: Inhibition of HIF-1±
by short hairpin RNA technology inhibits both in vitro and in vivo human
glioma cell growth. Accepted for presention at the World Federation of
Neuro Oncology, Edinburgh, Scotland, May 3-7, 2005.
138. Jensen RL: The use of animal models to study human
brain tumors. Presented at the District 8 AALAS meeting. Park City, Utah,
May 23, 2005.
139. Jensen RL and Gillespie DL: In vitro and in vivo
glioblastoma multiforme cell growth is inhibited by anti-HIF-1± short
hairpin RNA. Preliminary results and drug delivery studies. 40th Annual
Meeting of the Rocky Mountain Neurosurgery Society, Whistler, British
Columbia, June 18-22, 2005.
140. Samlowski W, Rao G, Klimo P, Thompson C, Wang M, Watson G, Shrieve
D, and Jensen RL. Stereotactic radiosurgery (SRS) as
therapy for melanoma brain metastases: Impact of added surgical resection
and whole brain radiotherapy. 6th World Congress on Melanoma. September
6-10, 2005, Vancouver, CA.
141. Jensen RL and Gillespie DL: Glioblastoma cell growth
is inhibited by anti-HIF1a- short hairpin RNA. Animal studies and drug
delivery techniques. Accepted for presentation at Congress of Neurological
Surgeons Annual Meeting October 9-13, 2005.
142. Jensen RL: Breakfast Seminar: Biology of meningiomas.
Accepted for presentation at Congress of Neurological Surgeons Annual
Meeting October 9-13, 2005. r construction.
|
